Skip to main content

Branded

  • PhRMA: 435 medicines in development targeting diabetes and other chronic conditions

    WASHINGTON — America’s biopharmaceutical research companies are developing 435 innovative new medicines to target 15 leading chronic conditions affecting the Medicare population, according to a new report released by the Pharmaceutical Research and Manufacturers of America last week.

    These medicines in development — all either in clinical trials or under review by the Food and Drug Administration — are diverse in scope. They include:

  • New England regional summit held to address opioid abuse

    NEW YORK — In an effort to address opioid drug abuse, governors of five New England states convened for a summit on Monday, the National Association of Boards of Pharmacy stated.

  • Novo Nordisk launches prefilled insulin device

    PLAINSBORO, N.J. — Novo Nordisk on Thursday announced the launch of Levemir FlexTouch (insulin detemir [rDNA origin] injection), a prefilled insulin delivery mechanism providing a new way for diabetics to administer their insulin.

    The device is the first and only prefilled insulin delivery system without a push-button extension, which helps to eliminate delivery challenges for the patient, according to the company.

  • Novartis seeks FDA approval for meningitis B vaccine

    BASEL, Switzerland — Novartis on Tuesday announced that it had submitted a biologic license application to the Food and Drug Administration for marketing approval for the use of Bexsero. The vaccine will help combat invasive meningococcal disease caused by serogroup B (meningitis B) in adolescents and young adults from ages 10 years through 25 years, according to the company.

  • Fight the Fakes anti-counterfeit medicine coalition adds 11 partners

    GENEVA — Following the campaign's six-month anniversary, Fight the Fakes last week announced 11 new partners, bringing the total number of member organizations to 25. New partners, representing wholesalers, pharmacists, mobile app services, coalitions for consumer protection and generic pharmaceutical manufactures, join the campaign to speak up and spread the word about the impact of fake medicines.

  • Moody's: New cancer drugs represent significant growth opportunity

    NEW YORK — New approaches to treating cancer are creating big growth opportunities for the pharmaceutical industry, Moody's Investors Service stated in a report released Thursday titled "Cancer Breakthroughs Bring New Options for Patients and Revenue Streams to Big Pharma." Drugs for the treatment of solid tumors in prevalent cancer types will serve a large and growing market, the report noted.

  • Study: Metformin with insulin associated with a higher risk of all-cause death

    CHICAGO — A study published Wednesday on JAMA's website found that diabetes patients taking metformin had a higher risk of all-cause death when insulin was added to their treatment as compared to when sulfonylureas were added to treatment.

  • FDA approves Valeant's Jublia

    LAVAL, Quebec — Valeant Pharmaceuticals International announced that its subsidiary, Valeant Pharmaceuticals North America, received approval from the Food and Drug Administration for its new drug application for Jublia (efinaconazole 10% topical solution). The drug is the first topical triazole approved for the treatment of onychomycosis of the toenails, the company said.

X
This ad will auto-close in 10 seconds